Present additional clinical data for the Phase 1 RTX-240 solid tumor trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 31 Mar 2021
- Delivered
- March 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Present additional clinical data for the Phase 1 RTX-240 solid tumor trial in early 2021”
What we found
Evidence strength A What the grades mean
The company reported initial clinical data from the RTX-240 Phase 1/2 solid tumor trial in March 2021, which falls within the early 2021 timeframe.
-
A Rubius Therapeutics, Inc. 10-Q filed 2021-05-10
“We reported initial clinical data from RTX-240 Phase 1/2 clinical trial in relapsed/refractory or locally advanced solid tumors in March 2021.” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- RTX-240 clinical data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Rubius Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C709401-021467 · Corrections policy